Premium
Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the S panish compassionate use program
Author(s) -
GarcíaGutiérrez Valentín,
MartinezTrillos Alejandra,
Lopez Lorenzo Jose Luis,
Bautista Guiomar,
Martin Mateos Maria Luisa,
AlvarezLarrán Alberto,
Iglesias Pérez Ana,
Romo Collado Andrés,
Fernandez Angeles,
Portero Angeles,
Cuevas Beatriz,
Ruiz Concepción,
Romero Esperanza,
Ortega Fernando,
Mata Isabel,
Tallón José,
García Garay Maria del Carmen,
Ramirez Sánchez María José,
de las Heras Natalia,
Giraldo Pilar,
Bobillo Sabela,
Guinea José María,
Deben Guillermo,
Valencia Sandra,
Sebrango Ana,
Boqué Concepción,
Maestro Begoña,
Steegmann Juan Luis
Publication year - 2015
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.23973
Subject(s) - bosutinib , medicine , nilotinib , dasatinib , imatinib , myeloid leukemia , oncology , tyrosine kinase inhibitor , gastroenterology , cancer
The role of bosutinib as rescue treatment of Philadelphia chromosome‐positive chronic myeloid leukemia (CML) patients after failing three previous tyrosine kinase inhibitors (TKIs) is currently unknown. We report here the largest series (to our knowledge) of patients treated with bosutinib in fourth‐line, after retrospectively reviewing 30 patients in chronic phase, and pretreated with imatinib, nilotinib, and dasatinib. With a median follow up of 11.1 months, the probability to either maintain or improve their CCyR response was 56.6% (17/30) and 11 patients (36.7%) achieved or maintained their baseline MMR. In patients not having baseline CCyR, the probabilities of obtaining CCyR, MMR, and MR4.5 were 13, 11, and 14%, respectively. The probabilities of obtaining MMR and deep molecular response MR4.5 in patients with baseline CCyR were 40.0% (6/15) and 20.0% (3/15). At 20 months, progression‐free survival was 73%. Grade 3–4 hematological toxicities were more frequent in resistant than intolerant patients (45.4 vs. 0.0%). Nonhematological toxicities were also more frequent in resistant patients, being diarrhea the most conspicuous one. Bosutinib seems to be an appropriate treatment option for patients resistant or intolerant to three prior TKI's.Am. J. Hematol. 90:429–433, 2015. © 2015 Wiley Periodicals, Inc.